R3 Bio
A biotechnology startup developing cell-based research platforms using cellular reprogramming and stem-cell-derived systems to create New Approach Methodologies (NAMs) that reduce reliance on animal testing.
- CEO / Founder
- John Schloendorn
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $1.0M
- Latest Round
- Seed
- Key Investors
- Tim Draper, Immortal Dragons, LongGame Ventures
Technology & Products
Key Products
Cell-based research platforms, stem-cell-derived model systems, New Approach Methodologies (NAMs) for preclinical research, computational analysis platforms.
Technological Advantage
Utilizes advanced CRISPR gene editing to 'knock out' brain development genes in stem cells, allowing for the growth of integrated organ systems in situ rather than isolated lab-grown organoids, which lack the systemic complexity required for accurate drug testing.
Differentiation
Value Proposition
Provides cell-based research platforms and New Approach Methodologies (NAMs) that reduce reliance on animal testing through stem-cell-derived systems and advanced analytical methods.
How They Differentiate
R3 Bio combines cellular reprogramming, stem-cell-derived systems, and computational analysis to build integrated biological signaling models that capture cross-cellular signals often lost in simpler assays, aligned with regulatory modernization efforts.
Market & Competition
Target Customers
Pharmaceutical companies, medical research institutions, contract research organizations (CROs), and eventually transplant hospitals.
Industry Verticals
["Biotechnology","Pharmaceuticals","Healthcare","Regenerative Medicine","Longevity & Life Extension"]
Competitors
Renewal Bio, eGenesis, Revalia Bio
Growth & Milestones
Growth Metrics
Transitioned from multi-year stealth mode to public R&D phase in March 2024; team size estimated at 1-10 employees.
Major Milestones
["Founded in 2021 by Alice Gilman and John Schloendorn.","Secured initial Seed funding from billionaire investor Tim Draper and Immortal Dragons in early 2024.","Emerged from stealth mode in March 2024 with major features in Wired and MIT Technology Review.","Updated company location to San Francisco (with upcoming second location in Puerto Rico) per website FAQ."]
Notable Customers
N/A (Currently in R&D/Pre-revenue stage)